Cancer immunotherapy: an evolving paradigm

作     者：Aifu LIN Aifu LIN

作者机构：MOE Laboratory of Biosystem Homeostasis and ProtectionCollege of Life SciencesZhejiang UniversityHangzhou 310058China Cancer CenterZhejiang UniversityHangzhou 310058China Key Laboratory for Cell and Gene Engineering of Zhejiang ProvinceHangzhou 310058China 

出 版 物：《Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)》 (浙江大学学报（英文版）B辑（生物医学与生物技术）)

年 卷 期：2022年第23卷第10期

页      面：791-792页

核心收录：

学科分类：0710[理学-生物学] 1002[医学-临床医学] 1001[医学-基础医学(可授医学、理学学位)] 100214[医学-肿瘤学] 0836[工学-生物工程] 10[医学] 

主　　题：immunotherapy clinical chemotherapy 

摘      要：The inhibition of the host’s natural immune response by tumor cells was widely reported in the early phases of the development of oncology therapy,and the concept of employing the host’s immune system to treat cancer,i.***.tumor immunotherapy,is not new.However,as a result of early theoretical constraints,clinical application of immunotherapy did not go smoothly and lagged significantly behind radiation and chemotherapy.The path has been winding,but the future now seems promising.Immunotherapy research has advanced enormously as a result of the maturing of immuno-editing theory and the creation of numerous technologies,despite a number of unsuccessful endeavors and clinical studies.Since around 1998,the US Food and Drug Administration(FDA)has approved a variety of tumor immunotherapies,including cytokines(interleukin-2,interferons),cancer vaccines(Provenge),immune checkpoint inhibitors(ipilimumab),and cellular therapies(chimeric antigen receptor-T(CAR-T)),signaling a boom in the field.